biotech · Alzheimer Disease · ABOS
Acumen Pharmaceuticals
Acumen Pharmaceuticals patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 66
- Programs
- 4
- Drugs
- 9
- Patents
- 6
Acumen Pharmaceuticals patents
6 pharmaceutical patents indexed for Acumen Pharmaceuticals. 0 expire within 24 months.
Acumen Pharmaceuticals has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 9320793
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
granted -
US 9217024
ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
granted -
US 9006283
Methods of modifying amyloid β oligomers using non-peptidic compounds
granted -
US 8962677
Methods of restoring cognitive ability using non-peptidic compounds
granted -
US 8507206
Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
granted -
US 7964359
Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
granted
Frequently asked questions
How many patents does Acumen Pharmaceuticals have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Acumen Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.